MX2017010993A - Agonista del receptor de angiotensina ii para tratar la fibrosis pulmonar. - Google Patents
Agonista del receptor de angiotensina ii para tratar la fibrosis pulmonar.Info
- Publication number
- MX2017010993A MX2017010993A MX2017010993A MX2017010993A MX2017010993A MX 2017010993 A MX2017010993 A MX 2017010993A MX 2017010993 A MX2017010993 A MX 2017010993A MX 2017010993 A MX2017010993 A MX 2017010993A MX 2017010993 A MX2017010993 A MX 2017010993A
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary fibrosis
- angiotensin
- receptor agonist
- receptor
- treating pulmonary
- Prior art date
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 title 1
- 108050000824 Angiotensin II receptor Proteins 0.000 title 1
- 101150116411 AGTR2 gene Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126880P | 2015-03-02 | 2015-03-02 | |
| PCT/GB2016/050552 WO2016139475A1 (en) | 2015-03-02 | 2016-03-02 | Angiotensin ii receptor agonist for treating pulmonary fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010993A true MX2017010993A (es) | 2018-04-11 |
Family
ID=55646777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010993A MX2017010993A (es) | 2015-03-02 | 2016-03-02 | Agonista del receptor de angiotensina ii para tratar la fibrosis pulmonar. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180078529A1 (enExample) |
| EP (1) | EP3265082A1 (enExample) |
| JP (1) | JP2018507244A (enExample) |
| KR (1) | KR20170122754A (enExample) |
| CN (1) | CN107405406A (enExample) |
| AU (1) | AU2016227486A1 (enExample) |
| BR (1) | BR112017018715A2 (enExample) |
| CA (1) | CA2977445A1 (enExample) |
| HK (1) | HK1244232A1 (enExample) |
| MX (1) | MX2017010993A (enExample) |
| WO (1) | WO2016139475A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017204163A1 (ja) * | 2016-05-23 | 2017-11-30 | 国立研究開発法人国立循環器病研究センター | 肺障害の予防または抑制用医薬 |
| CN111163793A (zh) | 2017-07-17 | 2020-05-15 | 莫纳什大学 | 血管紧张素受体激动剂及其用途 |
| US20210238229A1 (en) | 2018-06-14 | 2021-08-05 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| GB201917327D0 (en) | 2019-11-28 | 2020-01-15 | Vicore Pharma Ab | New pharmaceutical use |
| PH12022552413A1 (en) * | 2020-03-19 | 2024-01-08 | Vicore Pharma Ab | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii |
| GB202004094D0 (en) | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006081D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202007122D0 (en) | 2020-05-14 | 2020-07-01 | Vicore Pharma Ab | New process |
| GB202013721D0 (en) | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| GB202104033D0 (en) | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| EP4313953A1 (en) | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104038D0 (en) | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| CA3222721A1 (en) | 2021-07-09 | 2023-01-12 | Nadia Nasser PETERSEN | New selective angiotensin ii compounds |
| GB202115303D0 (en) | 2021-10-25 | 2021-12-08 | Vicore Pharma Ab | New formulation |
| WO2023140350A1 (ja) * | 2022-01-21 | 2023-07-27 | 国立大学法人 長崎大学 | 臓器の線維化抑制用医薬組成物 |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| CA3249539A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| CN114869866B (zh) * | 2022-05-05 | 2024-02-20 | 珠海瑞思普利医药科技有限公司 | 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法 |
| GB2640807A (en) * | 2022-12-22 | 2025-11-05 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| CN120569378A (zh) | 2023-01-09 | 2025-08-29 | 维科尔药物公司 | 选择性血管紧张素ii化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
| DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
| US8835471B2 (en) * | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| EP2832357A1 (en) * | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
-
2016
- 2016-03-02 AU AU2016227486A patent/AU2016227486A1/en not_active Withdrawn
- 2016-03-02 WO PCT/GB2016/050552 patent/WO2016139475A1/en not_active Ceased
- 2016-03-02 CN CN201680012711.8A patent/CN107405406A/zh not_active Withdrawn
- 2016-03-02 JP JP2017546725A patent/JP2018507244A/ja not_active Withdrawn
- 2016-03-02 BR BR112017018715-9A patent/BR112017018715A2/pt active Search and Examination
- 2016-03-02 KR KR1020177023949A patent/KR20170122754A/ko not_active Withdrawn
- 2016-03-02 US US15/554,213 patent/US20180078529A1/en not_active Abandoned
- 2016-03-02 MX MX2017010993A patent/MX2017010993A/es unknown
- 2016-03-02 CA CA2977445A patent/CA2977445A1/en not_active Withdrawn
- 2016-03-02 HK HK18103826.4A patent/HK1244232A1/zh unknown
- 2016-03-02 EP EP16712990.7A patent/EP3265082A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2977445A1 (en) | 2016-09-09 |
| AU2016227486A1 (en) | 2017-08-17 |
| HK1244232A1 (zh) | 2018-08-03 |
| US20180078529A1 (en) | 2018-03-22 |
| JP2018507244A (ja) | 2018-03-15 |
| CN107405406A (zh) | 2017-11-28 |
| KR20170122754A (ko) | 2017-11-06 |
| EP3265082A1 (en) | 2018-01-10 |
| WO2016139475A1 (en) | 2016-09-09 |
| BR112017018715A2 (pt) | 2018-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244232A1 (zh) | 用於治疗肺纤维化的血管紧张素ii受体激动剂 | |
| MX2023009483A (es) | Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia. | |
| PH12018500086A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MX2017006320A (es) | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. | |
| NZ737004A (en) | Triazole agonists of the apj receptor | |
| PL3556378T3 (pl) | Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca | |
| SG10201913331VA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11202002060XA (en) | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| IL251028A0 (en) | 17a,21-diesters of cortexolone for use in the treatment of tumors | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| WO2016107879A3 (en) | New use of angiotensin ii receptor agonists | |
| MX2017004510A (es) | Triazolopirazinonas como inhibidores de pde1. | |
| HK1254673A1 (zh) | 阿片受体配体和细胞色素p450抑制剂 | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| PL4101454T3 (pl) | Kompozycje do stosowania w leczeniu nadciśnienia | |
| PH12018550186A1 (en) | Pharmaceutical combinations for treating cancer | |
| IL271728A (en) | Materials, uses and treatment methods | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2015009153A (es) | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. | |
| IL286949A (en) | Mesitantan for use in the treatment of portopulmonary hypertension | |
| MX2018010174A (es) | INHIBIDORES DE INTERACCIONES DE RECEPTOR DE ß-ARRESTINA-NEUROCININ A 1 PARA EL TRATAMIENTO DEL DOLOR. | |
| NZ730759A (en) | 1,2-benzothiazole compounds for the treatment of kidney disorders | |
| TN2017000517A1 (en) | MULTl-PEPTIDE COMPOSITION | |
| BR112017008749A2 (pt) | métodos e composições para trombólise segura e eficaz |